据新华社报道,我国成功研发出人感染H7N9禽流感病毒疫苗株,这一成果打破和改变了我国流感疫苗株需由外国进口的历史,为及时应对新型流感疫情提供了有力的技术支撑,并为全球控制H7N9禽流感疫情作出了新的贡献。最近病毒疫苗株的成功研发为疫苗的制成将为时不远。截至10月24日,我国共报道136例H7N9禽流感病毒感染病例,病死亡高达33.1%,H7N9禽流感病毒疫苗株的研发成功,为我国打赢这场持久战 According to the Xinhua News Agency, China has successfully developed a human H7N9 bird flu virus vaccine strain, which has broken and changed the history of our country’s flu vaccine strains to be imported by foreign countries and provided a powerful technical support for timely response to the new influenza outbreak. It has made a new contribution to the global control of the outbreak of H7N9 bird flu. The recent successful development of a vaccine strain of vaccines will not be far behind. As of October 24, a total of 136 cases of H7N9 bird flu virus were reported in China, with a death rate of up to 33.1%. The successful development of the H7N9 bird flu virus vaccine strain has won the long-standing war for our country